ClinSpec Diagnostics reaches funding target of £3.5m
5th March 2021
Glasgow-based ClinSpec Diagnostics has secured an additional £1.1m investment, reaching its round two funding target of £3.5m.
ClinSpec, a spin-out company from the University of Strathclyde’s Department of Pure and Applied Chemistry, is aiming to develop liquid biopsies for the early detection of cancer.
The new £1.1m investment from the latest funding round comes from a range of investors, including Norcliffe Capital Limited, the University of Strathclyde, Eos Advisory and the founders.
The first £2.4m was secured in 2020, with that funding round led by Mercia’s EIS Funds with Scottish Enterprise, SIS Ventures, Eos Advisory and the University of Strathclyde.
Tumortherapie - Neuer Wirkstoff mit vielversprechendem Resultat bei Krebs
wienerzeitung.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from wienerzeitung.at Daily Mail and Mail on Sunday newspapers.
Tumorhemmender Wirkstoff mit Ruthenium: Vielversprechende Resultate
sn.at - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sn.at Daily Mail and Mail on Sunday newspapers.